Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT

Emd Lexigen Research Center Corp.

Emd Serono Research Center, Inc.

Christa Burger

Stephen D Gillies

Kin-Ming Lo

Werner Goebel

Siegfried Neumann

Peter Schubert

Winfried Linxweiler

Andreas Bubert

Martina Pawelzik

Kai Schiemann

Wolfgang Staehle

Johannes Gleitz

Dirk Wienke

Oliver Poeschke

Michael Busch

Mathias Frech

Hans-Joachim Mollenkopf

Gottfried Hofmann

Stefan Kohler

Stefan Köhler

The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.

Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist

Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.

Enhancing the circulating half-life of antibody-based fusion proteins

The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-colagen and/or platelet-collagen interaction is disclosed. Further, pharmaaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.

Glycoprotein VI fusion proteins

The invention relates to agents and processes for detecting bacteria of the genusin particularThe agents according to the invention include primers whose sequence is selected from the iap gene ofIn addition, the agents according to the invention include peptides whose sequence is selected from the p60 protein and which are suitable for producing specific antibodies for the immunological detection of

Processes and agents for detecting Listerias

The invention relates to agents and processes for detecting bacteria of the genus Listeria, in particular L. monocytogenes. The agents according to the invention include primers whose sequence is selected from the iap gene of L. monocytogenes. In addition, the agents according to the invention include peptides whose sequence is selected from the p60 protein and which are suitable for producing specific antibodies for the immunological detection of L. monocytogenes.

Processes and agents for detecting listerias

The invention relates to agents and methods for the immunological detection of bacteria of the genus Salmonella. The agents according to the invention include peptides whose sequence is selected from the PagC protein, and which are suitable for producing specific antibodies for the immunological detection of salmonellae.

Antibodies directed to pagC peptides for the detection of salmonellae

Growing community of inventors

Darmstadt, Germany

Christa Burger